

FACTSHEET

April 23, 2024

COMPANY PROFILE

Shenguan is principally engaged in the manufacture and sale of edible collagen sausage casing products, pharmaceutical products, food products, skin care and health care products and collagen medical devices.

COLLAGEN SAUSAGE CASINGS

In 2022, the Group carried out its work by centering on “stabilising quality, expanding new products and maintaining production capacity” in the collagen sausage casings industry. The Group continued to take stabilising the quality of collagen sausage casings products as its top priority, and implemented the accountability system and supervision system from the production segment to the sales segment to ensure the normal operation of facilities and equipment as well as proper production operation, so as to guarantee product quality. The Group strived to adjust the proportion of high-end casings and increasing the production and sales of high-end casings such as medium and large-sized diameter, and the sales volume of new products gradually increased. The Group had completed some R&D and technical renovation projects, through which the Group will increase production capacity and reduce production costs without increasing the sites. In terms of internal management, the Group continued to strengthen management awareness and clarify management responsibilities, implement and enhance supervision and standardise behaviours.

COLLAGEN FOOD PRODUCTS

The Group’s products already include collagen rice noodles, collagen drinks, beef tendon and collagen oat drinks. In order to enrich the product range, the Group obtained the production licence for collagen oat drinks during the Year and made various preparations for mass production.

COLLAGEN SKINCARE PRODUCTS


The Group further improved the quality of skincare products, continuously upgraded product formula, and developed a number of new products while improving the supporting of production capacity for each product. Related products will be launched on the market soon.

COLLAGEN MEDICAL DEVICES

Guangdong Victory Biotech Co., Ltd. (“Guangdong Victory”) and Wuzhou Victory Biotech Co., Ltd. (“Wuzhou Victory”) have obtained the dual certification of ISO13485 and ISO22442 from the European Union. We have filed the medical collagen raw materials on the website published by relevant state authorities, which will help improve the legal feasibility of customers’ selection of the Group’s medical collagen raw materials. The “collagen bone filling biomaterials (artificial bone) (膠原蛋白骨填充材料(人工骨))” have been approved by the Ethics Committee of Clinical Trials, and clinical trials are in progress in several hospitals. The Group’s “Preparation Method of Low Endotoxin Collagen (低內毒素膠原蛋白的製備方法)” was granted a national invention patent. We completed the installation of the “band-

aids “ production equipment, the Type I medical device products, with successful trial production. The Group was also in the process of the animal trials and discussions on clinical trial protocols for “in vivo absorbable hemostatic dressing (體內可吸收止血敷料)” and “medical beauty product (small beauty needle) (醫美產品(小美容針))” .

SHARE CHART



STOCK FUNDAMENTALS

ISIN	KYG8116M1087
Share Type	Ordinary
Bloomberg Code	829:HK
Ticker	829
Industry sector	Packaged Foods
Last Dividend	HKD 0.06
No. of shares	3,230,480,000
Market Cap	HK1.227B
52 week high	0.3400
52 week low	0.2600
Stock exchanges	Hong Kong Stock Exchange

KEY FIGURES

(RMB million, except where otherwise stated)	2022	2021
Revenue	1,032.2	1,168.1
Profit attributable to Owners of the Company	23.6	122.7
Basic Earnings Per Share (RMB cents)	0.7	3.8
Dividend Per Share (HK cents)		
– Final	2	2
– Special (Final)	4	4
Cash Inflow from Operation	106.0	179.7
Total Assets	3,354.4	3,312.1
Inventory Turnover Day – Raw Materials (days)*	39.8	37.4
Inventory Turnover Day – FG & WIP (days)*	152.5	159.6
Trade Receivables Turnover Day (days)*	70.2	56.0
Trade Payables Turnover Day (days)*	51.0	87.1

* Calculated based on the average value between the beginning of the year and the end of the year

	2022 Interim	2021 Interim
Revenue (RMB million)	430.8	506.0
Profit Attributable to Owners of the Company (RMB million)	13.5	61.2
Basic Earnings Per Share (RMB cents)	0.42	1.9
Interim Dividend Per Share (HK cents)	-	-
Cash Inflow from Operating Activities (RMB million)	(13.7)	(155.6)
Total Assets (RMB million)	3,358.0	3,216.4
Inventory Turnover Day – Raw Materials (days)	50.6	39.4
Inventory Turnover Day – FG & WIP (days)	195.4	198.3
Trade Receivables Turnover Day (days)	77.4	74.9
Trade Payables Turnover Day (days)	53.0	113.8

Shenguan Holdings (Group) Limited

Head Office: 29 Fudian Shangchong, Xijiang
Fourth Road, Wuzhou, Guangxi,
PRC
Tel and Fax: (86) 0774-2035538
Email: shenguan@shenguan.com.cn

IR Contact

Wonderful Sky Financial Group
Email: shenguan@wsfg.hk